What Neuroaid Treats: Main Uses and Benefits

The medication is commonly used as an add-on treatment to provide supportive relief for patients in situations where functional stability becomes affected following a neurological event. Neuroaid is generally applied when supportive symptom management is appropriate in conditions characterized by periods of heightened symptoms.

The medication is considered relevant across therapeutic domains involving Neurological Rehabilitation for established deficits related to Ischemic Stroke, Traumatic Brain Injury (TBI), and other central nervous system injuries.

Key Areas of Symptomatic Support

Neuroaid is considered relevant for easing symptom clusters that may become intense or disruptive, specifically motor impairments (like weakness), cognitive deficits (like difficulties with attention), and speech impairments (aphasia). It is applied across domains where additional symptomatic support is needed in situations where patients experience established functional deficits.

“The product is often used during phases when symptoms become more noticeable, providing support that helps ease the overall symptom burden.”

This supportive approach contributes to easing the overall symptom load and may assist with maintaining functional stability during periods requiring long-term symptomatic assistance.

Quick Fact	Description
Support for Deficits	Supports management of symptoms related to motor and cognitive impairments.
Use Context	Applied as adjunctive therapy during neurological rehabilitation.
Benefit Focus	Helps maintain stability and contributes to improved comfort.

Populations for Whom Use is Defined

Use of Neuroaid is approved for adult patients (typically 18 years and older) who are in the post-acute recovery phase following an ischemic stroke or traumatic brain injury (TBI). Eligibility is restricted to individuals who are medically stable and have established neurological deficits. The use in the pediatric population (children) is not documented and therefore cannot be recommended by regulatory authorities due to insufficient data.

Absolute Contraindications and Exclusions

The medicine is contraindicated for use in pregnant women and lactating/breastfeeding women, as stated in the prescribing information. Use is also strictly excluded in patients who have a known allergy to the active ingredients (MLC 601/MLC 901) or any component of the formulation.

Further exclusions apply to those with severe or unstable underlying systemic diseases, major comorbidities, or intracranial pathologies requiring surgical intervention, as established by regulator-approved patient profiles. Specific restrictions related to severe hepatic or renal impairment are typically covered by these broader systemic disease exclusions.

Interactions with Other Medicines and Products

Neuroaid (also known as MLC601 or MLC901) is often used as an add-on treatment and is generally considered safe for use alongside many standard medications. Clinical trials and safety monitoring have reported no widespread, significant drug interactions.

---

Common Co-administered Medications

Neuroaid has been safely combined with many drugs used in the management of stroke, traumatic brain injury, and associated conditions. These commonly include standard treatments for cardiovascular risk factors, such as antiplatelet agents (like aspirin), antihypertensives (blood pressure medicines), and cholesterol-lowering drugs (statins). Systematic trials have specifically shown no reported interaction between Neuroaid and aspirin.

---

Anticoagulants and Clotting

Clinical studies suggest that Neuroaid does not possess blood-thinning effects and has not been shown to affect standard clotting parameters in most patients. In patients taking oral anticoagulants, there have been reports of no impact on their International Normalized Ratio (INR), a measure of clotting time. However, due to the complexity of anticoagulant therapy and the potential for polypharmacy-related adverse events, close monitoring of INR and liver function is still recommended when initiating or adjusting Neuroaid in patients on anticoagulants. This is standard precautionary practice for combination therapies.

---

Consultation

As with any therapy, patients should always inform their physician or pharmacist about all other prescription medications, over-the-counter drugs, and herbal supplements they are taking to ensure comprehensive safety management.

Core Mechanism: Modulation of Neuroprotection and Cell Survival

Neuroaid's action begins at the cellular level by activating the PI3K/AKT survival pathway and inhibiting pro-apoptotic factors like caspase-3 and GSK-3β. This dual action modulates the signaling cascades associated with apoptosis and secondary damage in neurons and glia, resulting in the preservation of tissue structure after injury.

Neuroplasticity and Structural Circuit Development

The drug upregulates Brain-Derived Neurotrophic Factor (BDNF) and associated signaling, which fundamentally drives long-term neural organization. This effect promotes synaptogenesis and neurite outgrowth, resulting in the structural reorganization and development of new neural circuits within the central nervous system.

Modulation of Neuroinflammation and the Microenvironment

Neuroaid acts as an inhibitor of the neuroinflammatory cascade by modulating factors like NF-κB and specific cytokines. This dampening of the inflammatory response influences the local tissue microenvironment, which supports the processes of neurogenesis and neural circuit repair.

Support for Angiogenesis and Cerebral Blood Supply

A parallel mechanistic domain involves the promotion of angiogenesis via factors like VEGF and HIF-1α. This mechanism increases local microvascular density, which provides metabolic support for the active processes of neuroprotection and neuroplasticity.

The administration of Neuroaid (MLC 601) is defined by a standardized, fixed-dose regimen. As a multi-component agent supplied in a 400 mg capsule, the official route of administration is primarily oral.

Labeled Dosing and Administration

The standard adult regimen requires a divided-use frequency, with the total daily dose separated into three administrations. Each individual dose consists of four (4) capsules, making the standard total intake twelve (12) capsules per day. This protocol is maintained for a specific treatment course duration of three (3) months, and therapy is typically initiated as soon as possible following a neurological event.

Administration Component	Official Instruction
Route of Administration	Oral administration is standard. The capsule contents may be diluted for use via gastric tube.
Dosing Schedule	Four (4) capsules per dose, three times daily.
Course Duration	Three (3) months, to be initiated promptly.
Special Condition	Patients using oral anticoagulants must have their International Normalized Ratio (INR) monitored upon beginning the regimen.

Contextual Usage Principles

The medicine is used as an add-on therapy to complement standard clinical care and rehabilitation protocols. While the standard administration involves swallowing the capsules whole with water, the contents of the capsule can be opened and diluted for patients who have difficulty swallowing, thereby maintaining the integrity of the total daily dose. Prescribing information does not recommend or specify dosing adjustments for pediatric patients or pregnant/lactating women.

Research Evidence / Overview of Studies for Neuroaid

Evidence for use in Acute Ischemic Stroke (Initiation within 72 hours)

This section summarizes the structure of the high-quality research, including the large controlled studies, that examined the formulation's use shortly after an ischemic stroke event. It will detail the patient groups and the specific functional outcomes that researchers chose to measure in these studies.

Research explored how symptoms change over time in adults who had experienced an ischemic stroke of intermediate severity, where the study compound was studied for use within 72 hours of the event. The largest available controlled studies, which were placebo-controlled, reported that the primary measurement of functional independence at the initial 3-month follow-up was not different compared to the control group.

What remains uncertain is the interpretation of the main results, as the primary endpoint did not reach the established goal. Data collected from long-term follow-up studies extending up to 24 months are available but do not fully characterize outcomes for all aspects of recovery over that entire period.

---

Evidence for use in Subacute and Chronic Ischemic Stroke

This block will describe the types of studies, such as smaller-scale randomized controlled trials and observational data, that focused on patients who were already in the recovery phase after their stroke (subacute/chronic). It will outline the metrics used to assess changes in established motor and functional deficits in these populations.

Research was studied for use in adults enrolled in the post-acute phase of stroke, typically 2 weeks to 6 months after the event, where conditions marked by functional limitations were observed in the studies. Findings describe patterns observed in the studies, with outcomes measured over study periods often lasting 3 to 6 months.

Evidence quality varies across studies, with many being smaller or lacking rigorous control. There is limited information for long-term outcomes to fully characterize functional stability maintenance in these populations.

---

Evidence for use in Traumatic Brain Injury (TBI)

This heading covers the scope of research, including pilot studies and the available large controlled trials, that examined the formulation's use in individuals recovering from TBI. The summary will specify the cognitive functions and functional outcomes that were the primary focus of these TBI investigations.

Neuroaid was studied for use in adults presenting with cognitive impairment following mild to moderate TBI. The available large TBI trial reported that its primary endpoint, measuring changes in complex attention, was not different compared to the control group at the 6-month assessment. The overall evidence is limited due to the small number of studies.

Key Limitations and Areas of Research Uncertainty

A key limitation is that the large, high-quality controlled studies for acute stroke and TBI did not meet their primary endpoints for functional recovery. This means that while research describes patterns, the certainty remains low regarding a broad, defining outcome. The results apply only to the populations studied in the research and research does not determine whether an individual will respond similarly.

Key Studies & References

1. A Phase III Randomized, Controlled, Double-Blind Study of NeuroAiD II (MLC901) in Patients with Cognitive Impairment after Traumatic Brain Injury (TBI).

How to Store and Dispose of Neuroaid

Storage Conditions

To ensure product stability, Neuroaid must be stored according to official label instructions. The medicine requires specific environmental protection and must be kept sealed and stored in a cool and dry place.

Requirement	Condition (as per regulatory documents)
Temperature Limit	Do not store at a temperature exceeding 30 C (86 F).
Packaging Rule	Keep the capsules in the original packaging (e.g., blister pack) until consumption.
Protection Mandate	Protect from moisture and high heat.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Dispose of unused or expired Neuroaid in accordance with local laws and regulations for pharmaceutical waste. The preferred method is to use an authorized drug take-back program. If a take-back option is unavailable, follow established household disposal guidelines, which generally involve mixing the medicine with an unappealing substance, placing it in a sealed container, and discarding it with household trash.